European Union - English - EMA (European Medicines Agency)

glaxo group limited  - retigabine - epilepsy - antiepileptics, - trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group a polysaccharide 50ug;  ; neisseria meningitidis group c polysaccharide 50ug;  ; neisseria meningitidis group w135 polysaccharide 50ug;  ; neisseria meningitidis group y polysaccharide 50ug;   - suspension for injection - 50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 50ug   neisseria meningitidis group c polysaccharide 50ug   neisseria meningitidis group w135 polysaccharide 50ug   neisseria meningitidis group y polysaccharide 50ug   excipient: sucrose trometamol sodium chloride water for injection - mencevax acwy is indicated for active immunisation of adults and children over two years against meningococcal meningitis caused by group a, group c, group w-135 and group y meningococci. the vaccine may also be used for: · subjects who are close contacts of patients with disease caused by meningococci of groups a, c, w-135 and y. · travellers to countries where the disease is epidemic or highly endemic. · controlling epidemics of infection caused by group a, c, w-135, y meningococci in confined communities. mencevax acwy is not recommended for use in infants and children under two years of age, as antigenicity of the vaccine is low in this age group and antibodies persist for shorter duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - diphtheria crm197 protein, quantity: 16.7 microgram; meningococcal oligosaccharide group a, quantity: 10 microgram - injection, powder for - excipient ingredients: sucrose; monobasic potassium phosphate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group b factor h binding protein fusion protein 50ug; neisseria meningitidis group b neisseria adhesin a protein 50ug; neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug; neisseria meningitidis sergroup b outer membrane vesicles 25ug;   - suspension for injection - 0.5 ml - active: neisseria meningitidis group b factor h binding protein fusion protein 50ug neisseria meningitidis group b neisseria adhesin a protein 50ug neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug neisseria meningitidis sergroup b outer membrane vesicles 25ug   excipient: aluminium hydroxide histidine sodium chloride sucrose water for injection - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. see section 5.1 of the data sheet for information on protection against specific group b strains bexsero is indicated for vaccination of individuals from 2 months of age and older. the use of bexsero should be in accordance with official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group a polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 15 mcg of tetanus toxoid);  ; neisseria meningitidis group c polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 15 mcg of tetanus toxoid);  ; neisseria meningitidis group w135 polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 7.5 mcg of tetanus toxoid);  ; neisseria meningitidis group y polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 6.5 mcg of tetanus toxoid);   - powder for injection with diluent - active: neisseria meningitidis group a polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 15 mcg of tetanus toxoid)   neisseria meningitidis group c polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 15 mcg of tetanus toxoid)   neisseria meningitidis group w135 polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 7.5 mcg of tetanus toxoid)   neisseria meningitidis group y polysaccharide, tetanus toxoid conjugate 5ug (5 mcg polysaccharide conjugated to approx 6.5 mcg of tetanus toxoid)   excipient: sucrose tetanus toxoid trometamol hydrochloride sodium chloride water for injection - nimenrix is indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal disease caused by neisseria meningitidis groups a, c, w-135 and y

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.